An End-of-Study Subgroup Analysis of Black Patients from the Phase 2 Griffin Study of Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM)
Year: 2022
Type: article
Source: Blood
Authors: Ajay K. Nooka, Jonathan L. Kaufman, Cesar Rodriguez, Andrzej Jakubowiak, Yvonne A. Efebera, Brandi Reeves, Tanya M. Wildes, Sarah A. Holstein, Larry D. Anderson, Ashraf Z. Badros, Leyla O. Shune, Ajai Chari, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Paul G. Richardson, Saad Usmani, Peter M. Voorhees
Institutions: Emory University, Winship Cancer Institute, Emory University Hospital, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, University of Chicago Medical Center, OhioHealth, University of North Carolina at Chapel Hill, University of Nebraska Medical Center, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, University of Maryland, Baltimore, University of Kansas Medical Center, Janssen Scientific Affairs (United States), Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Memorial Sloan Kettering Cancer Center, Atrium Health Wake Forest Baptist, Levine Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310163549